Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  New England Journal of Medicine

• Publication date

  2005-03-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA050522PMID 15758000
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E

  2005cited by this paper
• Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E

  2005cited by this paper
• Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial.

  2005cited by this paper
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction

  2004cited by this paper
• Platelet-active drugs : the relationships among dose, effectiveness, and side effects.

  2004cited by this paper
• ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi

  2004cited by this paper
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects.

  2004cited by this paper
• Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

  2002cited by this paper
• Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.

  2001cited by this paper
• EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

  2001cited by this paper
• Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

  2001cited by this paper
• Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.

  2001cited by this paper
• Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.

  2000cited by this paper
• Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.

  2000cited by this paper
• Rationale, Design and Organization of the Second Chinese Cardiac Study (CCS-2): A Randomized Trial of Clopidogrel plus Aspirin, and of Metoprolol, among Patients with Suspected Acute Myocardial Infarction

  2000cited by this paper
• Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.

  1999cited by this paper
• Ticlopidine and clopidogrel.

  1999cited by this paper
• Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.

  1999cited by this paper
• The Antiaggregating and Antithrombotic Activity of Clopidogrel Is Potentiated by Aspirin in Several Experimental Models in the Rabbit

  1998cited by this paper
• A comparison of reteplase with alteplase for acute myocardial infarction.

  1998cited by this paper
• Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction.

  1997cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators.

  1995cited by this paper
• The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

  1993cited by this paper
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

  1993cited by this paper
• The open-artery theory is alive and well--again.

  1993cited by this paper
• Aspirin Versus Coumadin in the Prevention of Reocclusion and Recurrent Ischemia After Successful Thrombolysis: A Prospective Placebo‐Controlled Angiographic Study Results of the APRICOT Study

  1993cited by this paper
• Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.

  1991cited by this paper
• Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction.

  1991cited by this paper
• Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.

  1990cited by this paper
• Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.

  1990cited by this paper
• RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2

  1988cited by this paper
• Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial.

  1988cited by this paper
• Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

  1988cited by this paper
• The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

  1985cited by this paper
• HL-A AND INFECTIVE SACROILEITIS

  1974cited by this paper

• Antiplatelet drugs

  2025cites this paper
• Antiplatelet Therapy in Heart Disease

  2025cites this paper
• Demographic, risk factors, and management practices of patients with acute coronary syndrome: an observational study in a tertiary care hospital in Central India

  2025cites this paper
• 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• Protocolo terapéutico de la antiagregación y la anticoagulación en la cardiopatía isquémica

  2025cites this paper
• The Type of Preoperative Oral Antithrombotics as a Risk Factor for Venous Thromboembolism After Hip Surgery: A Retrospective Study

  2025cites this paper
• Embedding equity, diversity and inclusion processes within clinical trials and health and social care research

  2025cites this paper
• Early complications related to acute myocardial infarction: evolution over 20 years and risk factors. The ECAMI study.

  2025cites this paper
• Comparison of Platelet Function Tests for Long-Term Cardiovascular Events after Percutaneous Coronary Interventions

  2025cites this paper
• Bleeding Risk in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Comprehensive Review

  2025cites this paper
• National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Comprehensive Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025.

  2025cites this paper
• Heart Disease Mortality in the United States, 1970 to 2022

  2025cites this paper
• Optimizing selection of P2Y12 inhibiting therapy: clopidogrel, prasugrel or ticagrelor

  2025cites this paper
• Research Progress of Soluble sST2 in Heart Failure after Acute Myocardial Infarction

  2025cites this paper
• Role of intravenous P2Y12 inhibition in high-risk percutaneous coronary intervention.

  2025cites this paper
• Bleeding Outcomes of Ticagrelor Loading in STEMI Thrombolysis with Streptokinase and Tenecteplase: A Single-Centre Retrospective Study in a Malaysian Population

  2025cites this paper
• Association of a Comprehensive ST‐Segment–Elevation Myocardial Infarction Protocol With Key Process Metrics Among Patients Transferred for Primary Percutaneous Coronary Intervention

  2025cites this paper
• 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• The efficacy and safety of indobufen versus aspirin in patients with acute myocardial infarction: a retrospective observational study

  2025cites this paper
• Clopidogrel Influences Fracture Healing Under Ischemic Conditions

  2025cites this paper
• A history of the development of dual antiplatelet therapy for coronary artery disease.

  2025cites this paper
• Pharmacological Evaluation of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin Pretreatment on Infarct Artery Flow in Patients with Acute STEMI

  2025cites this paper
• Effect of P2Y12 Inhibitors on Major Adverse Cardiovascular Events After Coronary Artery Bypass Graft Surgery: A Population‐Based Cohort Study

  2025cites this paper
• Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population: DAPT-TR

  2024influential citation
• Fibrinolytic uses in the emergency department: a narrative review.

  2024cites this paper
• Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial infarction: a comprehensive review

  2024cites this paper
• Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population

  2024cites this paper
• Terapia Antiplaquetária Dupla Combinada em Pacientes com Doença Arterial Coronariana em uma População na Turquia: DAPT-TR

  2024influential citation
• STEMI Antithrombotic Therapy: The Evolving Role of P2Y12 Inhibitor Pretreatment in Contemporary Practice

  2024cites this paper
• Qishen Granule protects against myocardial ischemia by promoting angiogenesis through BMP2-Dll4-Notch1 pathway

  2024cites this paper
• Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis.

  2024cites this paper
• Evolution of REperfusion Strategies and impact on mortality in Old and Very OLD STEMI patients. The RESOVOLD-e-MUST study

  2024cites this paper
• Pharmacologie des médicaments antiplaquettaires

  2024cites this paper
• Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

  2024cites this paper
• Effect of cytochrome P450 2C19 (CYP2C19) gene polymorphism and clopidogrel reactivity on long term prognosis of patients with coronary heart disease after PCI.

  2024cites this paper
• Twenty Years of an Institutional Chest Pain Pathway: What’s Come and What’s Yet to Come

  2023cites this paper
• Italian contributions to the history of acute myocardial infarction treatment.

  2023cites this paper
• Medical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease.

  2023cites this paper
• Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?

  2023cites this paper
• Safety and efficacy of intracoronary thrombolytic agents during primary percutaneous coronary intervention for STEMI

  2023cites this paper
• Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI

  2023cites this paper
• Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)

  2023cites this paper
• Association between P2Y12 inhibitor reloading and in-hospital outcomes for patients with non-ST-segment elevation acute coronary syndrome already on chronic P2Y12 receptor inhibitors therapy in China: findings from the CCC–ACS (improving care for cardiovascular disease in China-acute coronary syndro

  2023cites this paper
• Thrombus remodelling by reversible and irreversible P2Y12 inhibitors

  2023cites this paper
• A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice

  2023cites this paper
• Anti-inflammatory Therapy Progress in Major Adverse Cardiac Events after PCI: Chinese and Western Medicine

  2023cites this paper
• Médicaments antiplaquettaires actuels et futurs

  2023cites this paper
• Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study

  2023cites this paper
• A nightmare of clopidogrel resistance in a resource-limited setting: case report of subacute stent thrombosis

  2023cites this paper
• Propuesta de manejo inicial del infarto de miocardio con elevación del segmento ST no complicado en centros sin capacidad de intervención coronaria percutánea en el Perú

  2023cites this paper
• Potent P2Y12 Inhibitor Monotherapy for Acute Coronary Syndrome.

  2023cites this paper
• Long-term risk, clinical management, and healthcare resource utilization of stable patients with coronary artery disease and post-myocardial infarction in Greece-TIGREECE study.

  2023cites this paper
• Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease

  2023cites this paper
• Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease—A Translational Perspective

  2023cites this paper
• Evaluation of the antiplatelet effect of generic ticagrelor 90 mg (ticaspan®) alone and in combination with aspirin 75 mg as compared to ticagrelor (innovator): An in vitro study

  2023cites this paper
• CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel

  2023cites this paper
• 2023 ESC Guidelines for the management of acute coronary syndromes.

  2023cites this paper
• Understanding clopidogrel resistance: Mechanisms, detections, implications and surmount the clopidogrel resistant in order to potential solutions

  2023cites this paper
• 2023 ESC Guidelines for the management of acute coronary syndromes.

  2023cites this paper
• Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.

  2023cites this paper
• An Integrated Multidisciplinary Circuit Led by Hospital and Community Pharmacists to Implement Clopidogrel Pharmacogenetics in Clinical Practice

  2023cites this paper
• Best Practices in Pharmacotherapy for Acute Coronary Syndromes

  2022cites this paper
• Epidemiological Characteristics and Risk Factors Associated with Acute Myocardial Infarction in Somalia: A Single-Center Experience

  2022cites this paper
• Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study

  2022cites this paper
• Antiplatelet Therapy in Coronary Artery Disease: Now and Then

  2022cites this paper
• Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status

  2022influential citation
• Current Status and Future Direction of Antithrombotic Therapy for Patients with STEMI Undergoing Primary PCI

  2022cites this paper
• Noninvasive In Vivo Coronary Artery Thrombus Imaging.

  2022cites this paper
• Genetic polymorphism of clopidogrel metabolism related gene CYP2C19 gene in Chinese from Foshan area of Guangdong Province

  2022cites this paper
• Comparison of tenecteplase versus alteplase in STEMI patients treated with ticagrelor: A cross-sectional study.

  2022cites this paper
• Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy

  2022cites this paper
• Antiplatelet Agents in Acute ST Elevation Myocardial Infarction.

  2022cites this paper
• Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction

  2022cites this paper
• A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes

  2022cites this paper
• ST‐Segment Elevation Myocardial Infarction

  2022cites this paper
• Antiplatelet therapy in cardiovascular disease: Current status and future directions

  2022cites this paper
• Sex differences in prehospital analgesia in patients presenting with acute coronary syndromes and their association with clinical outcomes

  2022cites this paper
• Approche pratique à la prescription des antiplaquettaires chez les patients atteints de syndromes coronariens

  2022cites this paper
• The Correlation Between MDR1 Gene Polymorphism and Clopidogrel Resistance in People of the Hui and Han Nationalities

  2022cites this paper
• Imaging of intracoronary thrombus

  2022cites this paper
• Clinical implications of diabetes mellitus in patients with acute coronary syndrome: prognostic role and use of new P2Y12 receptor inhibitors.

  2022cites this paper
• The Reduction of Mortality in Acute Myocardial Infarction: From Bed Rest to Future Directions

  2022cites this paper
• Reperfusion Strategies in Acute Myocardial Infarction: State of the Art

  2021cites this paper
• Drugs in Myocardial Infarction

  2021cites this paper
• Ticagrelor or clopidogrel dual antiplatelet therapy following a pharmacoinvasive strategy in ST‐segment elevation myocardial infarction

  2021influential citation
• Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum.

  2021cites this paper
• The Effects of Aspirin With Combined Compound Danshen Dropping Pills on Hemorheology and Blood Lipids in Middle-Aged and Elderly Patients With CHD: A Systematic Review and Meta-Analysis

  2021cites this paper
• Fibrinolytic Therapy in Patients with Acute ST-elevation Myocardial Infarction.

  2021cites this paper
• Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8.

  2021cites this paper
• Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race‐Conscious Medicine

  2021cites this paper
• Über den Autor

  2021cites this paper
• Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations

  2021cites this paper
• Management of ST Elevation Myocardial Infarction (STEMI) in Different Settings

  2021cites this paper
• Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.

  2021cites this paper
• Platelet physiology and pharmacology—relevant considerations for patient care

  2021cites this paper
• THROMBOLYTIC EFFICACY OF STREPTOKINASE IN ELDERLY TYPE 2 DIABETES MELLITUS WITH ACUTE ST ELEVATION MYOCARDIAL INFARCTION USING ELECTROCARDIOGRAPHIC ST-SEGMENT RESOLUTION

  2021cites this paper
• Anticoagulation and antiplatelet therapy post coronary artery bypass surgery

  2021cites this paper
• Prehospital Evaluation, ED Management, Transfers, and Management of Inpatient STEMI.

  2021cites this paper
• The TIMI Study Group’s Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-

  2021cites this paper
• Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygocity: a real-world study

  2021cites this paper